Source link : https://www.newshealth.biz/health-news/treating-advanced-breast-cancer-after-progression-on-cdk4-6-inhibitors/
The combination of abemaciclib (Verzenio) plus fulvestrant (Faslodex) significantly improved progression-free survival (PFS) versus fulvestrant alone in patients with hormone receptor-positive/HER2-negative advanced breast cancer who had disease progression on a CDK4/6 inhibitor and endocrine therapy, according to phase III data presented at the American Society of Clinical Oncology (ASCO) annual meeting. MedPage Today brought together […]
Author : News Health
Publish date : 2024-06-24 16:27:02
Copyright for syndicated content belongs to the linked Source.
Categories